Every 424B that Corbus Pharmaceuticals Holdings, Inc. (CRBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CRBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRBP filings page.
Corbus Pharmaceuticals Holdings, Inc. is establishing an at-the-market offering of its common stock under a shelf registration, allowing sales of up to $127,500,000 of shares from time to time through Jefferies LLC as sales agent. Jefferies may sell shares on Nasdaq under mutually agreed placement notices and will receive a 3% commission on gross proceeds, being deemed an underwriter for these transactions.
Assuming sales at $9.40 per share, the company illustrates issuance of 13,563,829 shares, which, together with prior sales, would increase common shares outstanding from 18,671,498 as of June 30, 2026 to up to 32,974,034. Pro forma as adjusted net tangible book value would rise to $228.7 million, or $6.94 per share, implying dilution of $2.46 per share to new investors relative to the assumed offering price. Corbus plans to use net proceeds primarily to advance its clinical pipeline, including CRB-701 in oncology and CRB-913 in obesity, and for general corporate purposes such as pre-clinical programs, working capital, potential acquisitions or investments, debt reduction and capital expenditures. The company highlights risks of share price volatility, potential dilution from existing equity awards and warrants, and uncertainty about the timing, pricing and total number of shares ultimately sold under the program.
Corbus Pharmaceuticals Holdings, Inc. registers an aggregate $300,000,000 shelf to offer common stock, preferred stock, warrants, debt securities, subscription rights and units under a shelf registration statement.
The prospectus states the offerings may be made separately or together in one or more offerings and that aggregate public offering price will not exceed $300,000,000. The document lists that 17,736,464 shares of common stock were issued and outstanding as of March 6, 2026.
Corbus Pharmaceuticals (CRBP) launched a public offering of 4,744,231 shares at $13.00 per share and 1,025,000 pre-funded warrants, together with 1,025,000 shares issuable upon warrant exercise. The company expects $70.5 million in proceeds before expenses and estimates approximately $70.2 million in net proceeds. Underwriters have a 30‑day option to buy up to 865,384 additional shares.
The pre-funded warrants are immediately exercisable at $0.0001 per share. Shares outstanding will be 18,528,517 after the offering (or 19,393,901 if the option is fully exercised), assuming full exercise of pre-funded warrants. Corbus plans to use proceeds to fund clinical development across its pipeline and for working capital and general corporate purposes.
As context, Corbus reported $104.0 million in cash, cash equivalents, and investments as of September 30, 2025, and has sold 505,217 shares via its ATM since June 30, 2025 for $6.7 million in gross proceeds. The filing’s dilution analysis indicates an immediate dilution of $2.96 per share to new investors at the offering price.
Corbus Pharmaceuticals (CRBP) launched a preliminary prospectus supplement for a primary offering of common stock and, at investors’ election, pre‑funded warrants, with the underwriters granted a 30‑day option to purchase additional shares. The pre‑funded warrants are immediately exercisable for one share at an exercise price of $0.0001 per share and include a 9.99% Beneficial Ownership Limitation (electable up to 19.99% with notice).
The company plans to use net proceeds to fund clinical development across its oncology and obesity programs and for working capital and general corporate purposes. As context, the stock last closed at $16.86 on October 29, 2025, and Corbus preliminarily estimates cash, cash equivalents, and investments of approximately $104.0 million as of September 30, 2025. Since June 30, 2025, it sold 505,217 shares via its at‑the‑market program for $6.7 million. Shares outstanding were 12,254,069 as of June 30, 2025, after giving effect to those ATM sales.